Just a little over a year after it emerged from stealth mode, the company - which recently initiated a clinical trial of a drug targeting allosteric mutations in solid tumors - has filed to go public.
The company joins a small but growing list of firms developing drugs targeting CD47, the "don't eat me" immune checkpoint. Another company, further ahead in development, is Forty Seven.
A new report from Relatient, A Data-Driven Guide to Patient Access Succes, highlights how focusing on data accuracy and relevance can enhance the performance of healthcare practices.
Second Genome uses genomics, computational biology and phenotypic screening to identify the molecular mechanisms of the microbiome that cause disease.
Scientists suspect there’s a connection between many common neurodegenerative diseases and malfunctioning lysosomes, or processing centers in human cells that break down proteins and eliminate debris. Now a new company called Lysosomal Therapeutics is tapping into the relationship between the two to discover and develop new treatments for rare diseases and common neurodegenerative diseases, starting […]